Dexcom G7 CGM Covered by Medicare; T1D Off-Label Drug Use; Another Tepezza Lawsuit

Dexcom announced that its G7 continuous glucose monitoring (CGM) system is now available to all Medicare patients with diabetes who meet the eligibility criteria, following the system launch last week.

Half of kids ages 5 and under don’t eat a daily vegetable and a third don’t eat a daily fruit, according to the CDC’s 2021 National Survey of Children’s Health. (Morbidity and Mortality Weekly Report)

Despite a decline in functional vision among people with 35-year-duration type 1 diabetes and proliferative diabetic retinopathy, these patients were able to maintain a decent quality of life. (Journal of Diabetes and its Complications)

Eating disorder specialists are worried that new childhood obesity guidance from the American Academy of Pediatrics may be harmful because it focuses on weight loss and BMI rather than health. (NPR)

A real-world study showed that off-label use of GLP-1 receptor agonists and SGLT2 inhibitors helped people with type 1 diabetes significantly lower their HbA1c levels. However, adverse events, like diabetic ketoacidosis, led to discontinuation in 26.9% of GLP-1 receptor agonist users and 27.7% of SGLT2 inhibitor users. (Journal of Clinical Endocrinology & Metabolism)

The FDA extended the review period for fezolinetant, an investigational nonhormonal treatment for moderate to severe vasomotor symptoms due to menopause, by 3 months, developer Astellas Pharma announced.

Horizon Therapeutics was hit with yet another lawsuit after allegedly failing to adequately warn patients about potential hearing loss linked to its thyroid eye disease drug teprotumumab (Tepezza). (AboutLawsuits.com)

A prespecified secondary analysis of a randomized trial supported the use of the standard dose of 400-IU vitamin D per day for bone mass — and not a higher 1,000-IU dose — for infants born with serum 25-hydroxyvitamin D concentrations less than 20 ng/mL. (JAMA Pediatrics)

The Idaho House of Representatives passed a bill criminalizing gender-affirming healthcare for minors, subjecting physicians to felony charges if they provide puberty blockers, hormone treatment, or gender-affirming surgeries to transgender youth under the age of 18. (NBC News)